Journal article
Role of trastuzumab in adjuvant therapy for locally invasive breast cancer
American journal of health-system pharmacy, Vol.63(6), pp.527-533
03/15/2006
DOI: 10.2146/ajhp050400
PMID: 16522889
Abstract
The role of trastuzumab in adjuvant therapy for locally invasive breast cancer is discussed.
Trastuzumab is a humanized monoclonal antibody that binds to the extracellular domain of human epidermal growth factor receptor-2 (HER2). Currently, trastuzumab is indicated for use in HER2-positive patients with metastatic breast cancer. Because trastuzumab specifically targets a receptor that is overexpressed in tumor cells, it is less likely to cause the cytotoxic adverse effects of traditional chemotherapy. Cardiotoxicity has been a major concern, however. Several trials were started to evaluate trastuzumab in the adjuvant setting in patients diagnosed with early-stage breast cancer. The interim results of these trials have shown a promising effect of adjuvant therapy with trastuzumab in improving overall survival, disease-free survival, relapse-free survival, and distant-disease-free survival.
The use of trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer can lead to increased survival. The appropriateness of trastuzumab therapy should be considered based on HER2 status, cost, and risk of toxicity.
Details
- Title: Subtitle
- Role of trastuzumab in adjuvant therapy for locally invasive breast cancer
- Creators
- Katie L Kabe - University of Wisconsin–MadisonJill M Kolesar - University of Wisconsin–Madison
- Resource Type
- Journal article
- Publication Details
- American journal of health-system pharmacy, Vol.63(6), pp.527-533
- DOI
- 10.2146/ajhp050400
- PMID
- 16522889
- ISSN
- 1079-2082
- eISSN
- 1535-2900
- Language
- English
- Date published
- 03/15/2006
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9984696556202771
Metrics
2 Record Views